FF hosted the EAI Developer Ecosystem Forum and the strategic launch of the FF EAI Brain & Open Developer Platform in San Francisco on April 25, officially opening recruitment for its global developer ecosystem and inviting the next generation of AI natives to create the future of embodied intelligence. The platform features six developer tools and four core infrastructure layers, with planned recruitment of three categories of developers spanning K‑12 students to professional engineers, pairing every contribution with a comprehensive developer incentive program, restructuring the value framework of the AI education ecosystem. Recruitment for the first batch of developer partners is
- Faraday Future Strategically Launches Its Embodied AI Developer Platform Purpose-Built for AI Natives, Marking 2026 as the Inaugural Year of EAI Robotics Education
- Large owner Corre Partners Management, Llc sold $1,882,704 worth of shares (703,669 units at $2.68) (SEC Form 4)
4 - NN INC (0000918541) (Issuer)
- President and CEO Mat Ishbia sold $11,186,417 worth of shares (3,001,722 units at $3.73) as part of a pre-agreed trading plan (SEC Form 4)
4 - UWM Holdings Corp (0001783398) (Issuer)
- PRESIDENT AND CEO Kurtz George sold $261,586 worth of shares (582 units at $449.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.03% to 2,213,973 units (SEC Form 4)
4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)
- Amendment: Chief Executive Officer Deller Colin James covered exercise/tax liability with 3,501 shares and was granted 7,001 shares, increasing direct ownership by 13% to 31,466 units (SEC Form 4)
4/A - ClearSign Technologies Corp (0001434524) (Issuer)
- Director Silva Gil Todd bought $10,569 worth of shares (2,000 units at $5.28), increasing direct ownership by 50% to 6,000 units (SEC Form 4)
4 - ClearSign Technologies Corp (0001434524) (Issuer)
- PRESIDENT AND CEO Kurtz George sold $1,966,503 worth of shares (4,418 units at $445.11) as part of a pre-agreed trading plan, decreasing direct ownership by 0.20% to 2,214,555 units (SEC Form 4)
4 - CrowdStrike Holdings, Inc. (0001535527) (Issuer)
- Co-Chairman Schwab Charles R. sold $6,579,331 worth of shares (72,900 units at $90.25) (SEC Form 4)
4 - SCHWAB CHARLES CORP (0000316709) (Issuer)
- SEC Form 3 filed by new insider Parker W Douglas
3 - AerCap Holdings N.V. (0001378789) (Issuer)
- Director Ballou Roger H sold $874,930 worth of shares (9,687 units at $90.32), decreasing direct ownership by 24% to 30,079 units (SEC Form 4)
4 - BREAD FINANCIAL HOLDINGS, INC. (0001101215) (Issuer)
- Quantum BioPharma Provides Corporate Update
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates. Quantum Biopharma has retained the services of Senergy Communications Capital Inc. ("Senergy") on a one-month contract with option for renewal, starting May 18, 2026, to provide marketing and investor awareness services. Senergy is an
- Director Dimaio John Michael was granted 100,000 shares, increasing direct ownership by 4% to 2,611,227 units (SEC Form 4)
4 - Spectral AI, Inc. (0001833498) (Issuer)
- DoubleU Games Announces Proposal to Acquire Remaining Publicly Held ADSs of DoubleDown Interactive
Proposed Buyout Would Unify the DoubleU Games Group and Enhance Operational Synergies and Capital Allocation EfficiencySEOUL, South Korea, April 27, 2026 /PRNewswire/ -- DoubleU Games Co., Ltd. (KRX: 192080) ("DoubleU Games" or the "Company") today disclosed that it has delivered a written proposal to the Board of Directors of DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) ("DDI") to acquire all issued and outstanding American Depositary Shares ("ADSs") of DDI not currently held by DoubleU Games at a price of $11.25 per ADS in an all-cash transaction (the "Transaction"), representing an aggregate value of approximately $184 million. Each ADS corresponds to one-twentieth (1/20) of one DDI comm
- Qfin Holdings Releases 2025 ESG Report
SHANGHAI, China, April 27, 2026 (GLOBE NEWSWIRE) -- Qfin Holdings, Inc. (NASDAQ:QFIN, HKEx: 3660)) ("Qfin Holdings" or the "Company"), a leading AI-empowered Credit-Tech platform in China, today published its annual ESG report for 2025. The report demonstrates Qfin Holdings's ESG-related guidelines, strategies and targets in 2025, highlighting the Company's efforts to environmental sustainability and social responsibility, the progress to improve corporate governance, and its ESG performance. In the future, Qfin Holdings will stay committed to enabling a better life for people by facilitating safe, convenient and inclusive financial services through technology empowerment to financial ins
- Volaris Reports Financial Results for the First Quarter 2026
MEXICO CITY, April 27, 2026 (GLOBE NEWSWIRE) -- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE:VLRS, BMV:VOLAR) ("Volaris" or "the Company"), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, today reports its unaudited financial results for the first quarter 20261. Enrique Beltranena, President & Chief Executive Officer, said: "Our first-quarter results reflect disciplined execution, as we strengthened revenue quality, optimized capacity deployment, and maintained cost control in a more challenging fuel environment. Demand remained solid across our network, supported by continued momentum in cross-border markets and strong top-
- Large owner Leonard Braden Michael sold $1,359,000 worth of shares (300,000 units at $4.53) (SEC Form 4)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
- Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") announces an educational webinar exploring the evolution of PSMA1-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating prostate cancer across the disease continuum. Dr. David N. Cade, Telix Group Chief Medical Officer will host a discussion with Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent's Hospital in Sydney, exploring what makes an effective PSMA-targeted therapy. Professor Emmett will showcase data from her OPTIMAL-PSMA2 investigator-initiated trial of TLX597-Tx (177Lu-DO
- Amendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.
SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)